254 related articles for article (PubMed ID: 25515823)
21. Extravasation emergencies: state-of-the-art management and progress in clinical research.
Pluschnig U; Haslik W; Bartsch R; Mader RM
Memo; 2016; 9(4):226-230. PubMed ID: 28058065
[TBL] [Abstract][Full Text] [Related]
22. Port-a-Cath-related complications in 252 patients with solid tissue tumours and the first report of heparin-induced delayed hypersensitivity after Port-a-Cath heparinisation.
Garajová I; Nepoti G; Paragona M; Brandi G; Biasco G
Eur J Cancer Care (Engl); 2013 Jan; 22(1):125-32. PubMed ID: 22966988
[TBL] [Abstract][Full Text] [Related]
23. Massive breast necrosis after extravasation of a full anthracycline cycle.
Vasconcelos I; Schoenegg W
BMJ Case Rep; 2013 Oct; 2013():. PubMed ID: 24142568
[TBL] [Abstract][Full Text] [Related]
24. Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.
Emoto S; Ishigami H; Hidemura A; Yamaguchi H; Yamashita H; Kitayama J; Watanabe T
Jpn J Clin Oncol; 2012 Nov; 42(11):1013-9. PubMed ID: 22872745
[TBL] [Abstract][Full Text] [Related]
25. Surgical management after doxorubicin and epirubicin extravasation.
Fleming A; Butler B; Gault D
J Hand Surg Br; 1999 Jun; 24(3):390. PubMed ID: 10433467
[No Abstract] [Full Text] [Related]
26. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
[TBL] [Abstract][Full Text] [Related]
27. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study.
Bertelli G; Gozza A; Forno GB; Vidili MG; Silvestro S; Venturini M; Del Mastro L; Garrone O; Rosso R; Dini D
J Clin Oncol; 1995 Nov; 13(11):2851-5. PubMed ID: 7595748
[TBL] [Abstract][Full Text] [Related]
28. Tissue distribution of epirubicin after severe extravasation in humans.
Nedomansky J; Haslik W; Pluschnig U; Kornauth C; Deutschmann C; Hacker S; Steger GG; Bartsch R; Mader RM
Cancer Chemother Pharmacol; 2021 Aug; 88(2):203-209. PubMed ID: 33907881
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy Extravasation: Establishing a National Benchmark for Incidence Among Cancer Centers.
Jackson-Rose J; Del Monte J; Groman A; Dial LS; Atwell L; Graham J; O'Neil Semler R; O'Sullivan M; Truini-Pittman L; Cunningham TA; Roman-Fischetti L; Costantinou E; Rimkus C; Banavage AJ; Dietz B; Colussi CJ; Catania K; Wasko M; Schreffler KA; West C; Siefert ML; Rice RD
Clin J Oncol Nurs; 2017 Aug; 21(4):438-445. PubMed ID: 28738039
[TBL] [Abstract][Full Text] [Related]
30. Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk.
Sauerland C; Engelking C; Wickham R; Corbi D
Oncol Nurs Forum; 2006 Nov; 33(6):1134-41. PubMed ID: 17149396
[TBL] [Abstract][Full Text] [Related]
31. [Subcutaneous "wash-out" in extravasations].
Giunta R; Akpaloo J; Kovacs L; Biemer E
Handchir Mikrochir Plast Chir; 2002 Nov; 34(6):399-402. PubMed ID: 12601608
[TBL] [Abstract][Full Text] [Related]
32. Port-A-Cath: a study of complication rates.
Robinson MO; Halverson P
S D J Med; 1991 Jul; 44(7):187-90. PubMed ID: 1925514
[TBL] [Abstract][Full Text] [Related]
33. Port-a-Cath complicated by infection or migration not removed by manual traction: usefulness of cardiac pacing leads extraction techniques.
De Lucia R; Segreti L; Soldati E; Di Cori A; Zucchelli G; Bongiorni MG
Ann Vasc Surg; 2013 May; 27(4):529-36. PubMed ID: 23540666
[TBL] [Abstract][Full Text] [Related]
34. A midline for oxaliplatin infusion: the myth of safety devices.
Masters B; Hickish T; Cidon EU
BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24903726
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy extravasation from implanted ports.
Schulmeister L; Camp-Sorrell D
Oncol Nurs Forum; 2000 Apr; 27(3):531-8; quiz 539-40. PubMed ID: 10785905
[TBL] [Abstract][Full Text] [Related]
36. Flow confirmation study for central venous port in oncologic outpatient undergoing chemotherapy: evaluation of suspected system-related mechanical complications.
Sofue K; Arai Y; Takeuchi Y; Sugimura K
Eur J Radiol; 2013 Nov; 82(11):e691-6. PubMed ID: 23916577
[TBL] [Abstract][Full Text] [Related]
37. Vesicant extravasation part II: Evidence-based management and continuing controversies.
Wickham R; Engelking C; Sauerland C; Corbi D
Oncol Nurs Forum; 2006 Nov; 33(6):1143-50. PubMed ID: 17149397
[TBL] [Abstract][Full Text] [Related]
38. Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer.
Pasello G; Carli P; Canova F; Bonanno L; Polo V; Zago G; Urso L; Conte P; Favaretto A
Anticancer Res; 2015 Apr; 35(4):2183-9. PubMed ID: 25862876
[TBL] [Abstract][Full Text] [Related]
39. Severe necrosis due to paclitaxel extravasation.
Herrington JD; Figueroa JA
Pharmacotherapy; 1997; 17(1):163-5. PubMed ID: 9017777
[TBL] [Abstract][Full Text] [Related]
40. Extravasations of oxaliplatin.
Kretzschmar A; Pink D; Thuss-Patience P; Dörken B; Reichert P; Eckert R
J Clin Oncol; 2003 Nov; 21(21):4068-9. PubMed ID: 14581435
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
